Literature DB >> 18021912

Changing smokeless tobacco products new tobacco-delivery systems.

Dorothy K Hatsukami1, Jon O Ebbert, Rachel M Feuer, Irina Stepanov, Stephen S Hecht.   

Abstract

Smokeless or noncombusted oral tobacco use as a substitute for cigarette smoking has been gaining greater interest and attention by the public health community and the tobacco industry. In order for the product to appeal to smokers, tobacco companies have been manufacturing new noncombusted oral tobacco (i.e., moist snuff) that is lower in moisture content and nitrosamine levels, packaged in small sachets and "spitless." While the primary motives of the major tobacco companies are to maintain or increase tobacco use, some members of the public health community perceive the use of noncombusted oral tobacco products as a harm reduction tool. Because cigarette smoking is associated with greater toxicant exposure compared to noncombusted oral tobacco, reduced mortality and morbidity are hypothesized to ensue, if cigarette smokers switched completely to these products. However, variability exists in levels of nicotine and toxicants and potential health consequences from use within and across countries. Therefore, promulgating noncombusted oral tobacco products as a safer alternative to smoking or as a substitute for smoking may engender more rather than less harm. To date, limited research is available on the effects of marketing noncombusted oral tobacco products to smokers, to support the use of these products as a harm reduction tool, and to determine the effects of varying levels of tobacco toxicants including nicotine on health. The need exists for manufacturing standards to lower toxicant levels of all noncombusted oral tobacco products, for the formulation of appropriate tobacco-product regulations and for the development of a strategic plan by the public health community to address this controversial topic.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18021912     DOI: 10.1016/j.amepre.2007.09.005

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  44 in total

1.  Delivery of nicotine in an extract of a smokeless tobacco product reduces its reinforcement-attenuating and discriminative stimulus effects in rats.

Authors:  Andrew C Harris; Irina Stepanov; Paul R Pentel; Mark G Lesage
Journal:  Psychopharmacology (Berl)       Date:  2011-09-30       Impact factor: 4.530

2.  Smokeless tobacco marketing and sales practices in Appalachian Ohio following federal regulations.

Authors:  Elizabeth G Klein; Amy K Ferketich; Mahmoud Abdel-Rasoul; Mei-Po Kwan; Loren Kenda; Mary Ellen Wewers
Journal:  Nicotine Tob Res       Date:  2012-02-07       Impact factor: 4.244

3.  A pilot randomized study of smokeless tobacco use among smokers not interested in quitting: changes in smoking behavior and readiness to quit.

Authors:  Matthew J Carpenter; Kevin M Gray
Journal:  Nicotine Tob Res       Date:  2010-01-06       Impact factor: 4.244

Review 4.  Biomarkers of exposure to new and emerging tobacco delivery products.

Authors:  Suzaynn F Schick; Benjamin C Blount; Peyton Jacob; Najat A Saliba; John T Bernert; Ahmad El Hellani; Peter Jatlow; R Steven Pappas; Lanqing Wang; Jonathan Foulds; Arunava Ghosh; Stephen S Hecht; John C Gomez; Jessica R Martin; Clementina Mesaros; Sanjay Srivastava; Gideon St Helen; Robert Tarran; Pawel K Lorkiewicz; Ian A Blair; Heather L Kimmel; Claire M Doerschuk; Neal L Benowitz; Aruni Bhatnagar
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-05-18       Impact factor: 5.464

5.  Animal models to assess the abuse liability of tobacco products: effects of smokeless tobacco extracts on intracranial self-stimulation.

Authors:  Andrew C Harris; Laura Tally; Clare E Schmidt; Peter Muelken; Irina Stepanov; Subhrakanti Saha; Rachel Isaksson Vogel; Mark G LeSage
Journal:  Drug Alcohol Depend       Date:  2014-12-23       Impact factor: 4.492

6.  Perceived Health Risks of Snus and Medicinal Nicotine Products.

Authors:  Dorothy K Hatsukami; R I Vogel; Herb H Severson; Joni A Jensen; Richard J O'Connor
Journal:  Nicotine Tob Res       Date:  2015-09-18       Impact factor: 4.244

7.  Smokeless tobacco products harbor diverse bacterial microbiota that differ across products and brands.

Authors:  Eoghan M Smyth; Prachi Kulkarni; Emma Claye; Stephen Stanfill; Robert Tyx; Cynthia Maddox; Emmanuel F Mongodin; Amy R Sapkota
Journal:  Appl Microbiol Biotechnol       Date:  2017-04-22       Impact factor: 4.813

8.  The use of snus for quitting smoking compared with medicinal products.

Authors:  Karl Erik Lund; Ann McNeill; Janne Scheffels
Journal:  Nicotine Tob Res       Date:  2010-07-09       Impact factor: 4.244

Review 9.  Review of epidemiologic data on the debate over smokeless tobacco's role in harm reduction.

Authors:  David S Timberlake; Jason A Zell
Journal:  BMC Med       Date:  2009-10-19       Impact factor: 8.775

10.  Surveillance indicators for potential reduced exposure products (PREPs): developing survey items to measure awareness.

Authors:  Karen Bogen; Lois Biener; Catherine A Garrett; Jane Allen; K Michael Cummings; Anne Hartman; Stephen Marcus; Ann McNeill; Richard J O'Connor; Mark Parascandola; Linda Pederson
Journal:  Harm Reduct J       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.